Vor Biopharma Inc Stock News

Intend to announce updated clinical data from Phase 1/2 VBP301 trial of VCAR33 ALLO in the first half of 2025 and updated clinical data from Phase 1/2a VBP101 trial of trem-cel in combination with Mylotarg in the second half of 2025

CAMBRIDGE, Mass., Dec. 09, 2024 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced updated clinical data from its ongoing Phase 1/2 VBP101 study of patients with relapsed/refractory AML receiving trem-cel followed by Mylotarg™. The data, which was presented in a poster at the American Society of Hematology (ASH) Annual Meeting on Sun...

CAMBRIDGE, Mass., Sept. 30, 2024 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced the appointment of Han Choi, M.D., LL.M., as its new Chief Financial Officer, effective immediately. Dr. Choi will join the Vor Bio leadership team and will report directly to the company's President and Chief Executive Officer, Dr. Robert Ang.

CAMBRIDGE, Mass., Sept. 05, 2024 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced new clinical data from its ongoing Phase 1/2 VBP101 study of patients with relapsed/refractory AML receiving trem-cel followed by Mylotarg™. The data demonstrated reliable engraftment, shielding from Mylotarg on-target toxicity, a broadened Mylotarg t...

CAMBRIDGE, Mass., Aug. 28, 2024 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that it will participate in the following upcoming investor conferences:

CAMBRIDGE, Mass., Aug. 08, 2024 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today reported financial results for the three-month period ended June 30, 2024, and provided a corporate update.

CAMBRIDGE, Mass., Aug. 02, 2024 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that, effective as of July 31, 2024, the Compensation Committee of the Board of Directors granted stock options to purchase an aggregate of 1,250 shares of Vor Bio's common stock and restricted stock units (“RSUs”) representing the right to receive an ...

CAMBRIDGE, Mass., July 09, 2024 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that, effective as of July 1, 2024, the Compensation Committee of the Board of Directors granted stock options to purchase an aggregate of 3,000 shares of Vor Bio's common stock and restricted stock units (“RSUs”) representing the right to receive an a...